Introduction
Apoptosis is a major mechanism of programmed cell death used by metazoan organisms to eliminate superfluous and irreparably damaged cells (Danial and Korsmeyer, 2004) . It has a crucial role in shaping organs during development and controls homeostasis and integrity of tissues throughout life Chowdhury et al., 2006) . Apoptosis can be triggered by a wide variety of stimuli, including developmental cues, severe cellular stress or damage to essential cellular components, caused by heat shock, radiation, cytotoxic drugs, infection and oncogenic transformation. Aberrant regulation of apoptotic cell death mechanisms is an important pathological factor in a variety of major human diseases (Fadeel et al., 1999) . Deficiency in apoptosis is one of the key hallmarks of cancer (Hanahan and Weinberg, 2000) and also contributes to certain autoimmune diseases (Prasad and Prabhakar, 2003) and metabolic disorders (McKenzie et al., 2004) . In contrast, excessive apoptosis is an important component in neurodegenerative disorders such as Alzheimer's and Huntington's disease (Rohn et al., 2001; Sanchez Mejia and Friedlander, 2001) , stroke (Prunell et al., 2005) , ischemic heart disease (Hayakawa et al., 2002) , AIDS (Casella and Finkel, 1997) and infertility (Said et al., 2004) . In mammalian cells, apoptosis induction occurs through two distinct pathways: intrinsic and extrinsic. The intrinsic pathway is activated by intracellular events and depends on the release of proapoptotic factors from the mitochondria (Danial and Korsmeyer, 2004) . The extrinsic pathway receives signals through the binding of extracellular protein ligands to proapoptotic death receptors (DRs), located on the cell surface (Ashkenazi and Dixit, 1998) . Both pathways lead to hierarchical activation of specialized cysteine-aspartate proteases called caspases (Lavrik et al., 2005b; Li and Yuan, 2008) . Apoptotic signals first activate initiator caspases, including caspase-2, -8, -9 and -10, by inducing their oligomerization at multiprotein platforms (Chen et al., 2002; Boatright et al., 2003; Bouchier-Hayes et al., 2009) . Once stimulated, initiator caspases proteolytically activate the downstream effector caspases, including caspase-3, -6 and -7, which in turn cleave numerous essential cellular proteins, thereby leading to the unique morphological and biochemical features of apoptosis, such as plasma membrane 'blebbing', cell shrinkage, chromatin condensation and internucleosomal DNA fragmentation.
The intrinsic pathway involves mitochondrial outermembrane permeabilization (MOMP) and consequent release of apoptogenic factors, such as cytochrome c, AIF and Smac-DIABLO, from the mitochondria into the cytoplasm (Green and Reed, 1998; Kroemer et al., 1998; Wang, 2001) . Cell-intrinsic stimuli control MOMP through the proteins of the Bcl-2 family (van Loo et al., 2002) . Members of this family are evolutionarily conserved and can be divided into three subgroups, according to function or structural similarity within four Bcl-2-homology domains (designated BH1-4) (Petros et al., 2004; Youle and Strasser, 2008) . The BH3-only proapoptotic proteins are activated by transcriptional or post-translational mechanisms in response to specific cellular stress conditions (for example, Bik by endoplasmic reticular stress, Bim and Bad by cytokine deprivation, Puma and Noxa by DNA damage). Once activated, BH3-only proteins promote oligomerization of the multi-BH domain proapoptotic proteins Bax and Bak in the mitochondrial outer membrane, thereby inducing MOMP. In contrast, the multi-BH domain antiapoptotic members, such as Bcl-2, Bcl-X L and Mcl-1, inhibit MOMP induction by neutralizing specific proapoptotic family members. The release of apoptogenic factors from the mitochondria causes numerous cellular changes that commit the cell to death and is therefore considered 'the point of no return' in the intrinsic pathway (Green and Amarante-Mendes, 1998 ). In the cytosol, cytochrome c induces the assembly of a multimeric complex called the apoptosome, containing the adaptor protein Apaf-1 and the apoptosis-initiating protease caspase-9. The apoptosome mediates the clustering and activation of caspase-9 (Li et al., 1997) , which goes on to process and activates effector caspases (Rodriguez and Lazebnik, 1999) . The X chromosomelinked inhibitor of apoptosis protein (XIAP) provides an important checkpoint to prevent inadvertent caspase activation: XIAP binds to caspases-3, -7 and -9 through its baculovirus IAP repeat domains and inhibits caspase activity (Deveraux et al., 1998; Salvesen and Duckett, 2002; Eckelman et al., 2006; Varfolomeev and Vucic, 2008) . However, release of mitochondrial Smac, which antagonizes XIAP, can override this checkpoint (Verhagen et al., 2000; Srinivasula et al., 2001) .
The extrinsic pathway transmits signals from extracellular ligands through proapoptotic DRs to the apoptotic caspase machinery (Ashkenazi and Dixit, 1998) . Depending on cell type, the extrinsic and intrinsic pathways may converge (Ozoren and El-Deiry, 2002; Barnhart et al., 2003; LeBlanc and Ashkenazi, 2003) . In mammals, the extrinsic pathway has an important role in regulating various aspects of immunity. Under physiological conditions, it participates in selection and maintenance of the immune repertoire and regulates the immune response (Opferman and Korsmeyer, 2003; Wilson et al., 2009) . Furthermore, the extrinsic pathway helps remove infected, transformed or damaged cells. Natural killer cells and cytotoxic T lymphocytes express proapoptotic ligands of the TNF superfamily, which recognize specific DRs on the surface of target cells. Binding of these ligands to their cognate DRs results in the assembly of a death-inducing signaling complex (DISC). The DISC stimulates the initiator proteases caspase-8 and -10, thereby driving downstream effector caspase activation and apoptosis (Peter and Krammer, 2003) .
Among the proapoptotic ligands, Apo2L/TRAIL; (TNFSF10) has emerged as a promising candidate for cancer therapy by virtue of its ability-as a soluble, zinccoordinated homotrimeric protein-to trigger apoptosis in various types of cancer cells without significant toxicity toward normal cells (Ashkenazi et al., 1999; Lawrence et al., 2001; Ashkenazi, 2002) . Clinical studies in cancer patients are currently underway to evaluate the safety and efficacy of recombinant human Apo2L/ TRAIL (dulanermin) and of several agonistic antibodies that activate its proapoptotic receptors, DR4 or DR5 (Ashkenazi et al., 2008) . This review discusses the current understanding of the biological role of Apo2L/ TRAIL and highlights new insights into the molecular events that mediate apoptosis signaling by this ligand. Such insights may aid in the development of cancer therapies based on Apo2L/TRAIL and its receptors.
DRs
DRs: distinct members of the TNFR superfamily DRs belong to the TNF receptor (TNFR) superfamily, which comprises more than 20 proteins, involved in diverse biological functions ranging from the regulation of cell death or survival to differentiation and immunity (Nagata, 1997; Ashkenazi and Dixit, 1998; Krammer, 2000) . Similar to other TNFRs, DRs are type I transmembrane proteins that contain cysteine-rich extracellular domains (CRDs) (Figure 1 ). They are uniquely characterized, however, by a relatively conserved cytoplasmic 'death domain' (DD) of B80 amino acids, which is essential for transmitting the apoptotic signal. To date, six DRs have been identified: TNFR1 (TNFRSF1A), Fas (also known as CD95, APO-1 or TNFRSF6), DR3 (TNFRSF12), DR4 (also known as TRAILR1 or TNFRSF10A), DR5 (also known as TRAILR2 or TNFRSF10B) and DR6 (TNFRSF21) (Figure 1 ). Extensive studies on TNFR1, Fas, DR4 and DR5, with their respective cognate ligands, TNF-a (TNFSF2), Fas ligand (FasL or TNFSF6) and Apo2L/TRAIL (TNFSF10), have been reported in the literature. DR6 has recently emerged as a crucial component of a neuronal self-destruction pathway associated with Alzheimer's disease (Nikolaev et al., 2009) . The extracellular fragment of the b-amyloid precursor protein (N-APP), characteristic to Alzheimer's brain pathology, binds DR6 and triggers neuronal degeneration through activation of caspase-6.
On ligation, DRs recruit DD-binding adaptor proteins-either Fas-associated DD (FADD) or TNFRassociated DD (TRADD)-which then promote the assembly of multiprotein signaling complexes. Although all DRs possess a DD, they can be distinguished by the pivotal adaptor protein they recruit and the consequent signaling complex they assemble. Fas, DR4 and DR5 typically bind to FADD to form the DISC and activate apoptosis (Algeciras-Schimnich et al., 2003; Lavrik et al., 2005a; Wilson et al., 2009) . In contrast, TNFR1 and DR3 usually recruit TRADD to assemble distinct signaling complexes that regulate cellular responses such as survival, differentiation or proliferation. The molecular mechanism that transmits signals from DR6 to caspase-6 is not yet well understood. The complexes assembled by DRs often share common components, facilitating cross-talk between different signaling pathways downstream. For example, in addition to promoting cell survival through nuclear factor (NF)-kB, under certain circumstances, TNFR1 may also induce cell death through the assembly of two alternative signaling platforms (complex IIa and IIb), both of which recruit FADD and caspase-8 (Wilson et al., 2009) . Similarly, under specific conditions, DR4 and/or DR5 may trigger the NF-kB and mitogenactivated protein kinase (MAPK) pathways, by promoting the recruitment of RIP1, TRAF2 and NEMO/ IKK-g into a secondary intracellular complex seeded downstream of the DISC by FADD and caspase-8 (Varfolomeev et al., 2005) .
Apo2L/TRAIL and its death and decoy receptors Proapoptotic DR ligands characteristically exist as type II transmembrane proteins that can be displayed on the cell surface or released into the extracellular milieu on cleavage by metalloproteases. Apo2L/TRAIL was discovered independently in two laboratories, as a novel proapoptotic member of the TNF superfamily (Wiley et al., 1995; Pitti et al., 1996) . In human cells, it activates apoptosis through its cognate DD-containing receptors, DR4 and/or DR5 (Figure 1 ). Apo2L/TRAIL also interacts with three 'decoy' receptors that are unable to transmit apoptotic signals, namely, DcR1 (TRAILR3 or TNFRSF10C) (Pan et al., 1997; Sheridan et al., 1997) , DcR2 (TRAILR4 or TNFRSF10D) (Degli- Esposti et al., 1997; Marsters et al., 1997) and osteoprotegerin (OPG or TNFRSF11B) (Emery et al., 1998) . DcR1 is anchored to the plasma membrane through a glycophospholipid moiety and lacks an intracellular domain, whereas DcR2 is a transmembrane protein harboring a truncated, nonfunctional DD. OPG is a soluble protein, mainly involved in inhibiting osteoclast formation and bone resorption by blocking the interaction of RANKL (TNFSF11) with its cellsurface receptor RANK (TNFSFR11A). Apo2L/ TRAIL binds to OPG, although with a lower affinity, and this has been proposed to regulate differentiation and survival of mature osteoclasts (Zauli et al., 2004 (Zauli et al., , 2008 Vitovski et al., 2007) . However, considering that Apo2L/TRAIL-knockout mice are viable and develop normal bone density (Cretney et al., 2002; NewsomDavis et al., 2009) , it remains unclear whether this ligand has a significant physiological role in regulating osteoclastogenesis (Labrinidis et al., 2008) .
Biological role of Apo2L/TRAIL Although the ability of Apo2L/TRAIL to trigger apoptosis in certain transformed cells is well established, its physiological role is not fully defined. This ligandreceptor pathway is well conserved throughout vertebrate evolution. In zebrafish, the Apo2L/TRAIL pathway is not crucial for proper embryonic development but capable of triggering apoptosis in cells of the erythroid lineage (Eimon et al., 2006) . In contrast to humans, mice possess only one cognate DR for Apo2L/ TRAIL, dubbed mDR5 (or mTRAILR2 and mKIL-LER), which shares a similar degree of homology with human DR4 and DR5 (Wu et al., 1999) . mDR5-knockout mice are viable and develop normally (Diehl et al., 2004) . Similarly, Apo2L/TRAIL-knockout mice do not display any overt developmental defects, indicating that, as in zebrafish, Apo2L/TRAIL signaling is not essential for normal mouse embryonic development (Cretney et al., 2002) . Apo2L/TRAIL is expressed specifically on the surface of natural killer cells, cytotoxic T cells, macrophages and dendritic cells, and transcription of its mRNA can be induced by type I Apoptosis signaling by Apo2L/TRAIL F Gonzalvez and A Ashkenazi interferons (Almasan and Ashkenazi, 2003) . Its selective expression in immune effector cells suggests that Apo2L/TRAIL may contribute to shaping the immune repertoire and/or regulating the immune response. Genetic ablation of either Apo2L/TRAIL or mDR5 in mice does not affect the resting immune cell populations (T, B, macrophage, dendritic and natural killer cells) (Cretney et al., 2002; Diehl et al., 2004) . Patients with multiple sclerosis or systemic lupus erythematosus have elevated serum levels of Apo2L/TRAIL, suggesting upregulation of this ligand in certain autoimmune disorders (Wandinger et al., 2003; Lub-de Hooge et al., 2005) . Apo2L/TRAIL-knockout mice displayed defective thymocyte apoptosis and accelerated autoimmunity (Lamhamedi-Cherradi et al., 2003) . Furthermore, treatment of wild-type mice with Apo2L/TRAILblocking antibodies exacerbated development of experimental autoimmune disease (Hilliard et al., 2001; Cretney et al., 2005) . Infection of mDR5-knockout mice with murine cytomegalovirus was associated with an augmented antiviral response (Diehl et al., 2004) . Consistent with this latter possibility, Apo2L/TRAILdeficient mice displayed enhanced resistance to Listerial infection (Zheng et al., 2004) . Together, these results suggest that Apo2L/TRAIL may have a role in curtailing the immune response to avoid excessive reaction to self-antigens or infectious agents.
Other studies have suggested that Apo2L/TRAIL may function as a tumor suppressor by participating in immune surveillance against primary and metastatic tumors. In mice, either antibody blockade or genetic ablation of Apo2L/TRAIL supports a role for this ligand in the suppression of experimental and spontaneous tumor metastasis in vivo (Takeda et al., 2001; Cretney et al., 2002) . Recently, comparison of geneexpression profiles in a panel of 368 human breast tumor samples revealed that downregulation of Apo2L/ TRAIL correlates with breast cancer metastasis to the brain (Bos et al., 2009) . Moreover, a significant increase in metastasis of lymphoma and skin carcinoma has been observed in mDR5-knockout mice (Finnberg et al., 2008; Grosse-Wilde et al., 2008) . Although there is good evidence for antimetastatic activity of Apo2L/TRAIL, the importance of the endogenous ligand for controlling initiation and growth of primary tumors is still a matter of debate. Apo2L/TRAIL-knockout mice did not spontaneously develop tumors and deletion of the gene in either p53 null or APC min mice did not affect tumorigenesis (Yue et al., 2005) . Apo2L/TRAIL deficiency also did not affect the initiation of skin cancer in response to chemical carcinogen (Grosse-Wilde et al., 2008) . On the other hand, loss of Apo2L/TRAIL promoted the development of methylcholanthreneinduced fibrosarcomas in mice (Cretney et al., 2002) . Furthermore, deletion of one mDR5 allele was sufficient to promote lymphomagenesis in mice expressing an Em promoter-driven Myc transgene in B lymphocytes (Finnberg et al., 2008) . These discrepancies may result from different mouse genetic backgrounds, tumor induction protocols or tissue specificity of tumor suppression by Apo2L/TRAIL. Apart from this, a definitive role of endogenous Apo2L/TRAIL as a suppressor of tumor initiation, progression and/or metastasis in humans has yet to be established.
There is also evidence for a role of Apo2L/TRAIL signaling in radiosensitivity: mDR5-knockout mice were found to develop bronchopneumonia and lung cancers in response to sublethal doses of ionizing radiation (Grosse-Wilde et al., 2008) . More recently, DR5 has been implicated in the regulation of detachment-induced cell death (anoikis) in colorectal carcinoma cell lines (Laguinge et al., 2008) . The underlying mechanisms and physiological significance of the involvement of DR5 in radiation responses and anoikis remain to be defined.
Apoptosis signaling by Apo2L/TRAIL
Structure of Apo2L/TRAIL and its complex with DR5 Human Apo2L/TRAIL is a 281 amino acid, type 2 transmembrane glycoprotein that can be cleaved from the cell surface to form a soluble ligand (Wiley et al., 1995; Pitti et al., 1996) ; however, the physiological function of the soluble protein has not been fully determined. Its C-terminal extracellular domain shares clear homology with other TNF superfamily members, whereas the N-terminal domain does not. The structure of the C-terminal domain (residues 96-281 or 114-281) has been defined by X-ray crystallography (Cha et al., 1999; Hymowitz et al., 1999 Hymowitz et al., , 2000 . Similar to other members of the TNF superfamily, Apo2L/TRAIL is a homotrimeric molecule, with each monomer being composed of two antiparallel b-sheets. However, a unique property of Apo2L/TRAIL is that it contains a central zinc atom at the trimer interface. The zinc ion binds to the cysteine-230 sulfhydryl of each monomer and helps to maintain the ligand in its trimeric structure (Hymowitz et al., 2000) . This cysteine-zinc coordination is important for the solubility, stability and biological activity of Apo2L/TRAIL (Cha et al., 1999; Hymowitz et al., 1999 Hymowitz et al., , 2000 Bodmer et al., 2000; Lawrence et al., 2001) . The C-terminal domain of Apo2L/TRAIL also has been crystallized in complex with the extracellular region of DR5 (residues 1-130) (Hymowitz et al., 1999; Mongkolsapaya et al., 1999) . The extracellular region of DR5 is composed of three CRDs of approximately 40 residues, each with six cysteines that form three disulfide bridges. The Apo2L/TRAIL-DR5 complex contains three receptors, nestled into the long crevices between pairs of monomers of the homotrimeric ligand (Hymowitz et al., 1999) . The binding site of Apo2L/TRAIL is located in CRD2 and CRD3 of DR5. The Apo2L/ TRAIL-DR5 interface consists of two distinct patches: patch B is common to the TNF superfamily and engages hydrophobic interactions, whereas patch A controls receptor specificity and cross-reactivity (Hymowitz et al., 1999 (Hymowitz et al., , 2000 .
Preligand receptor association TNFR superfamily members were initially thought to exist as monomers that trimerize on binding of their Apoptosis signaling by Apo2L/TRAIL F Gonzalvez and A Ashkenazi cognate trimeric ligands. However, substantial evidence now indicates that certain TNFRs are preassembled into oligomers before ligation (Chan, 2007) . Preligand association was first detected for Fas, TNFR1 and TNFR2 (Papoff et al., 1999; Chan et al., 2000; Siegel et al., 2000) , which appear to form homotypic trimers in the absence of ligand. A preligand assembly domain (PLAD), located in the first CRD of the receptor, mediates the association between monomers. Subsequently, PLAD-dependent association has been reported for DR4 and DR5 (Clancy et al., 2005) . Overexpression experiments suggest that the ECDs of DR4 and DR5 can interact either with each other or with the ECD of DcR2; the latter may disrupt the formation of DR4 or DR5 homotrimers. However, these observations should be interpreted with caution, given that heterotypic preassociation has not been confirmed with endogenously expressed receptors. Rare ECD mutations in DR4 and DR5 have been identified in lung cancers (Lee et al., 1999; Fisher et al., 2001) , although it is unknown whether these mutations enhance or diminish receptor-receptor association. Better understanding of how preligand assembly of DR4 or DR5 is regulated may spawn new strategies to sensitize tumors to Apo2L/TRAIL-mediated apoptosis.
The DISC Ligation of DR4 or DR5 by trimeric Apo2L/TRAIL promotes further clustering of the receptors into highmolecular-weight complexes and drives formation of the DISC (Wagner et al., 2007) . The Apo2L/TRAIL DISC has been well characterized. As the FasL DISC, it is composed of oligomerized receptors, the adaptor molecule FADD, the initiator proteases caspase-8 and/ or caspase-10, and, depending on the context, the cellular FLICE-inhibitory protein (c-FLIP) Kischkel et al., 2000 Kischkel et al., , 2001 Sprick et al., 2000 Sprick et al., , 2002 Wang et al., 2001; Sharp et al., 2005) . The stoichiometry of the different DISC components has not been fully defined. On ligand stimulation, DR4 and DR5 recruit FADD through DD interactions. FADD then recruits caspase-8, -10 and/or c-FLIP to the complex through homophilic death effector domain (DED) interactions. DISC assembly promotes the autoprocessing and activation of caspase-8 and -10 and releases the enzymes into the cytoplasm. In turn, caspase-8 and -10 cleave and activate the effector caspases, caspase-3, -6 and -7, which execute the apoptotic death program (Figure 2 ). Caspase-8 and -10 are recruited to and processed at the DISC with similar kinetics and may function independently of each other (Kischkel et al., 2001; Wang et al., 2001; Sprick et al., 2002) . Unlike caspase-8, an ortholog of human caspase-10 does not exist in the mouse; therefore, it is possible that caspase-10 may substitute for caspase-8 in some human cells. In one study, caspase-10 transfection did not restore the sensitivity of caspase-8-deficient cells to Apo2L/TRAIL-mediated apoptosis (Sprick et al., 2002) ; however, in two other studies, transient transfection of caspase-10 isoforms significantly restored sensitivity (Kischkel et al., 2001; Wang et al., 2001) . Embryonic fibroblasts from caspase-8-knockout mice were resistant to Fas and TNFR1-mediated apoptosis, but retained sensitivity to cell-intrinsic apoptotic stimuli such as DNA damage (Varfolomeev et al., 1998) . Further investigation is therefore required to determine more precisely whether human caspase-8 and -10 have redundant or distinct roles.
In response to DR ligation, the antiapoptotic protein c-FLIP can also be recruited to the DISC through homotypic DED interactions with FADD. c-FLIP shares structural homology with caspase-8 and -10, but lacks a catalytic cysteine residue and hence, enzymatic activity (Krueger et al., 2001; Thome and Tschopp, 2001) . At least 10 splice variants of c-FLIP have been identified, but only three are detected in humans: two short variants, c-FLIP s and c-FLIP R ; and one long splice form, c-FLIP L , c-FLIP s , consists of two tandem DEDs with a short C-terminal tail and inhibits DR-mediated apoptosis by competing with caspase-8 and -10 for association with FADD (Irmler et al., 1997; Thome et al., 1997) . In contrast, c-FLIP L contains two N-terminal DEDs and two catalytically inactive caspase-like domains at the C-terminus. The function of c-FLIP L at the DISC is more complex; although overexpression of c-FLIP L protected cells from apoptosis (Irmler et al., 1997; Thome et al., 1997) , ectopic expression of c-FLIP L at lower levels promoted caspase-8 activation and apoptosis induction (Chang et al., 2002; Micheau et al., 2002) . Selective knockdown of c-FLIP L enhanced the recruitment, activation and processing of caspase-8 at the DISC and sensitized various cancer cells to Apo2L/TRAIL-mediated apoptosis . Mouse embryo fibroblasts with c-FLIP knockout showed enhanced sensitivity to extrinsic apoptosis signaling (Yeh et al., 2000) . Taken together, these results suggest that at large amounts, c-FLIP L may exert an antiapoptotic effect at the DISC by competing for the recruitment of caspase-8 and -10; in contrast, when present in lower amounts, c-FLIP L may heterodimerize with caspase-8 or -10 at the DISC and support apoptosis activation. Recent work further underscores the importance of c-FLIP by demonstrating that APC tumor suppressor mutation and consequent b-catenin stabilization in colorectal cancer cells downregulates c-FLIP L expression, but the cells remain resistant to Apo2L/TRAIL; treatment with retinoic acid upregulates DR4 and DR5, overcoming this resistance (Zhang et al., 2010) .
Type I and II signaling by Apo2L/TRAIL Depending on cell type, apoptosis activation through the extrinsic pathway may or may not depend on the intrinsic pathway (Scaffidi et al., 1998) . This difference has been characterized initially in the Fas/FasL system. In 'type I' cells, the DISC activates sufficient caspase-8 to stimulate the executioner caspases directly and thereby induce apoptosis. By contrast, 'type II' cells appear to generate less active caspase-8 at the DISC and their commitment to apoptosis requires further signal amplification through the intrinsic/mitochondrial pathway. This is achieved by caspase-8-mediated processing of the BH3-only protein Bid to its active form tBid, which consequently engages Bax or Bak to induce MOPMP Luo et al., 1998) . Although both type I and type II cells display Bid cleavage and undergo MOMP following exposure to FasL or Apo2L/ TRAIL, these latter events are required for extrinsic apoptosis activation only in type II cells (Scaffidi et al., 1998; Ozoren and El-Deiry, 2002) . Hepatocytes from mice expressing a human Bcl-2 transgene were protected from Fas-induced apoptosis, whereas Bcl-2 transgenic T Binding of the homotrimeric Apo2L/TRAIL ligand to DR4 and DR5 drives the clustering of the receptors into highmolecular-weight complexes and leads to assembly of the DISC. O-glycosylation of DR4 and DR5 and palmitoylation of DR4 facilitate ligand-induced receptor clustering. This promotes receptor binding of the adaptor protein FADD, which in turn recruits the initiator caspases 8 and 10 and/or the caspase-8/10 inhibitor c-FLIP to the DISC. The receptor-associated DISC moves into a membrane compartment that is enriched in lipid rafts and linked to the cytoskeleton. Here, caspase-8 comes into contact with a CUL3/ RbxI-based E3 ligase complex, which catalyzes polyubiquitylation of caspase-8 on its C-terminal region. This modification is counterbalanced by the deubiquitylation enzyme A20, which can physically interact with the DISC. Polyubiquitylated caspase-8 associates with the ubiquitin-binding protein p62/sequestosome-1, which promotes the translocation of caspase-8 from the DISC into intracellular ubiquitin-rich foci. This localization likely increases the focal concentration of caspase-8, facilitating its full activation. In 'type I' cells, the DISC activates sufficient caspase-8 to stimulate the effector caspases 3, 6 and 7 and directly induce apoptosis. However, 'type II' cells generate less-active caspase-8 at the DISC and their commitment to apoptosis requires further signal amplification by the intrinsic/mitochondrial pathway. This is achieved by caspase-8-mediated cleavage of the BH3-only protein Bid into tBid, which rapidly translocates to the mitochondria and drives (through Bax and Bak) permeablization of the outer mitochondrial membrane, releasing mitochondrial cytochrome c and Smac. Once in the cytosol, cytochrome c binds to the adaptor Apaf-1 to recruit the initiator caspase-9 into a signaling complex called apoptosome. Activated caspase-9 then cleaves and activates the effector caspases. Release of Smac augments apoptosis by antagonizing the inhibitory effect of XIAP on effector caspases. In type II cells, blocking the mitochondrial pathway by overexpression of Bcl-2 and Bcl-X L inhibits apoptosis activation by Apo2L/TRAIL. The binding of Apo2L/TRAIL also promotes clathrin-mediated DR4/DR5 internalization. However, the biological fate of the internalized ligand-receptor complexes remains unresolved. Besides activating caspases, Apo2L/TRAIL may stimulate intracellular kinase cascades such as IKK, JNK, p38 MAPK and PKB/Akt pathways. In this case, Apo2L/TRAIL promotes the formation, downstream of the DISC, of an intracellular complex (called complex II) composed of FADD, TRADD, caspase-8, caspase-10, RIP1, TRAF2 and IKK-g (NEMO). The physiological role of the activation of these intracellular kinase cascades by Apo2L/TRAIL has yet to be elucidated. Indeed, evidence to the contrary suggests that in the mouse, DR5 may function to suppress NF-kB activity.
Apoptosis signaling by Apo2L/TRAIL F Gonzalvez and A Ashkenazi cells and thymocytes remained sensitive (Strasser et al., 1995; Lacronique et al., 1996) . Similar results were obtained with Bax/Bak double-knockout mice and in Bid-deficient mice (Yin et al., 1999; Lindsten et al., 2000; Wei et al., 2001) . Moreover, overexpression of Bcl-X L in mice protected B cells against Fas-induced apoptosis (Schneider et al., 1997b) . These data indicate that thymocytes and T cells respond in type I mode, whereas hepatocytes and pancreatic b cells behave in type II manner vis-a-vis Fas signaling. Further evidence supports the existence of similar type I versus II mechanisms in Apo2L/TRAIL signaling as well (Figure 2 (Ryu et al., 2001) , pancreatic carcinoma (Elnemr et al., 2001) , malignant melanoma (Irmler et al., 1997 ) and Burkitt's lymphoma (Tepper and Seldin, 1999) . Another potential determinant is XIAP. Ablation of the XIAP gene in mice or treatment with a Smac mimetic drug enabled Fas-mediated apoptosis to occur independently of Bid in hepatocytes and B cells (Jost et al., 2009) . Moreover, downregulation of XIAP bypassed the requirement for mitochondrial amplification and sensitized type II cells to apoptosis stimulation by FasL, Apo2L/TRAIL or anti-DR5 agonist antibody (Vogler et al., 2008; Varfolomeev et al., 2009) . Hence, the ratios of c-FLIP to caspase-8 and XIAP to Smac together may determine whether cells respond in type I or II mode to DR ligation. Analysis of sensitivity to FasL in tumor cell lines suggests that type I cells tend to express mesenchymal-like genes, whereas type II cells express epithelial-like genes (Algeciras-Schimnich et al., 2003) . Furthermore, high and low levels of the miRNA let-7 were found in epithelial type II cells and mesenchymal type I cells, respectively, while let-7 expression inversely correlated with disease progression in ovarian cancer (Shell et al., 2007) . Thus, it has been proposed that cancer cells with a type II versus type I response to FasL may represent different stages of carcinogenesis that resemble the epithelial-mesenchymal transition (Shell et al., 2007) . Whether the same applies to apoptotic signaling in response to Apo2L/TRAIL requires further study.
Recent advances in understanding apoptosis initiation
The interest in Apo2L/TRAIL as a potential anticancer agent has motivated an intensive effort to gain better knowledge of the molecular events underlying apoptosis signaling by this ligand and its cognate DRs. Sensitivity to Apo2L/TRAIL seems to be controlled mainly by apical events such as DISC assembly and caspase-8 activation (Wagner et al., 2007; Hughes et al., 2009) . Consistent with this notion, a study examining apoptosis stimulation in individual cells within a culture has demonstrated that differences in the extent of caspase-8 activation may be responsible for cell-to-cell variation in Apo2L/TRAIL responsiveness (Spencer et al., 2009) . Other investigations have led to further advances in our understanding of the regulation of receptor clustering, the role and mechanism of receptor internalization, and the control of caspase-8 activation.
Regulation of DR4 and DR5 clustering by posttranslational modification Post-translational modifications of DR4 and DR5 by glycosylation or palmitoylation have emerged as important modulators of the initiating events of Apo2L/ TRAIL signaling. O-glycans are attached to proteins through serine and threonine residues, while N-glycosylation occurs at asparagine residues. Specific O-glycosylation enzymes may provide important biomarkers to predict the sensitivity of cancer cells to Apo2L/TRAIL (Wagner et al., 2007) . Comparison of the gene-expression profiles of a panel of 119 cancer cell lines revealed that elevated expression of the O-glycosylation-initiating enzyme, GALNT14, strongly correlates with sensitivity of pancreatic carcinoma, nonsmall cell lung cancer and malignant melanoma cell lines, whereas high expression of another initiating enzyme, GALNT3, along with the O-glycan-processing enzymes, FUT3 and FUT6, strongly correlated with sensitivity of colorectal cancer cell lines. Modulation of the activity of these enzymes by loss-or gain-of-function strategies specifically affected apoptotic responsiveness to Apo2L/TRAIL, but not to other extrinsic and intrinsic stimuli. Moreover, depletion of certain O-glycosylation enzymes attenuated caspase-8 activation at the DISC, whereas overexpression of GALNT14 augmented DISC formation and sensitized cells to Apo2L/TRAIL. Further biochemical analysis revealed that the ECD of DR5 undergoes O-linked glycosylation at specific sites. These sites were found to be highly conserved in DR4, but absent in Fas and TNFR1, which may account for the selective effect of O-glycosylation on Apo2L/TRAIL. O-glycosylation did not significantly alter the expression of DR4 and DR5 at the cell surface or their ligand-binding affinity. Instead, receptor O-glycosylation appeared to be required for efficient ligand-induced clustering of DR4 and DR5, which triggers DISC assembly and caspase-8 activation. Clustering of the Fas receptor has been shown to depend on the generation of ceramide-enriched membrane microdomains by acid sphyngomyelinase (Grassme et al., 2001 (Grassme et al., , 2003 . Similarly, several studies have suggested a role of ceramide-rich platforms in signaling Apoptosis signaling by Apo2L/TRAIL F Gonzalvez and A Ashkenazi by DR4 and DR5 (Martin et al., 2005; Dumitru et al., 2007) . A putative N-glycosylation site has been noted on DR4 (Pan et al., 1997) , although not conserved on DR5 . Furthermore, specific pharmacologic inhibition of N-glycosylation has been shown to alter the clustering of DR4 but not DR5 (Yoshida et al., 2007) . Precisely how the modification of DR4 and DR5 by O-linked or N-linked sugars modulates receptor trafficking and/or signaling has yet to be elucidated. Palmitoylation of DRs has been implicated as well in the regulation of extrinsic apoptosis signaling (Chakrabandhu et al., 2007; Feig et al., 2007; Rossin et al., 2009) . Fas and DR4 (but not TNFR1 and DR5) were found to be constitutively palmitoylated in cancer cells. Mutational analysis revealed that DR4 is palmitoylated on a triplet of cysteines located between the receptor's transmembrane and DD region (Rossin et al., 2009 ). Similar to Fas, inhibition of DR4 palmitoylation affected the ability of DR4 to transduce extrinsic apoptotic signals (Rossin et al., 2009 ). Pharmacological inhibition and overexpression studies suggested that palmitoylation of DR4 is required for its localization to lipid rafts and ability to form trimers in the absence of ligand (Rossin et al., 2009) . Whether the expression levels of specific palmitoyl transferases affect the responsiveness of cancer cells to Apo2L/TRAILinduced apoptosis requires further investigation.
Internalization of DR4 and DR5 and its effect on Apo2L/TRAIL signaling The binding of a ligand to a cognate cell-surface receptor often triggers rapid endocytosis of the resulting ligand-receptor complex. Internalization can occur by clathrin-mediated, caveolin-mediated, or clathrin-and caveolin-independent endocytosis. The clathrin-and caveolin-mediated endocytotic pathways involve recruitment of the ligand-receptor complex into specific membrane invaginations, respectively known as clathrincoated pits and caveolae; both depend on the GTPase dynamin to release the resulting vesicles into the cytoplasm. In contrast, clathrin-and caveolin-independent endocytosis involves lipid rafts but does not rely on dynamin. Once formed, endocytic vesicles generated through these three pathways fuse with early endosomes (Le Roy and Wrana, 2005) . Endocytosis has long been considered solely as a mechanism that terminates signaling by targeting receptors for lysosomal degradation. However, in the past decade it has become apparent that internalization and intracellular trafficking of receptors also can have a stimulatory role in certain signaling pathways. Internalization and compartmentalization of TNFR1 and Fas following ligand binding may have a key role in directing signal transduction (Schutze et al., 2008) . Clathrin-mediated endocytosis of TNFR1 and Fas has been shown to be required for apoptosis stimulation, but not for activation of the NF-kB and MAPK pathways. It has been reported that in response to TNF or FasL, DISC components are directly recruited to internalized receptors residing in endosomal compartments, dubbed receptosomes (Schneider-Brachert et al., 2004 Lee et al., 2006) . By contrast, recruitment of the signaling complexes that drive NF-kB and MAPK activation in response to TNFR1 or Fas ligation occurs at the cell surface and does not rely on receptor internalization (Schneider-Brachert et al., 2004 Lee et al., 2006) . Recent work suggests that actin polymerization and internalization events are required for Fas activation by agonistic antibody but not FasL (Chaigne-Delalande et al., 2009) . The role of receptor internalization in Apo2L/TRAIL signaling has recently been explored. Both DR4 and DR5 rapidly internalize in response to ligation, through a dynamin-dependent mechanism (Austin et al., 2006; Kohlhaas et al., 2007) . Inactivation of dynamin using a temperature-sensitive, dominant-interfering dynamin mutant blocked ligandinduced internalization of DR5 at the nonpermissive temperature in HeLa and BJAB cells (Austin et al., 2006) . DR5 specifically localized to clathrin-coated pits on ligation (Austin et al., 2006) and blocking the assembly of such structures abrogated Apo2L/TRAIL internalization in BJAB cells (Kohlhaas et al., 2007) .
Together, these results demonstrate that Apo2L/TRAIL promotes clathrin-mediated DR5 internalization. However, in contrast to TNFR1 and Fas signaling, receptorligand internalization was not required for Apo2L/ TRAIL-mediated DISC formation and apoptosis (Austin et al., 2006; Kohlhaas et al., 2007) . Two independent studies indicated that inactivation of dynamin in BJAB and HeLa cells increases, rather than inhibits, Apo2L/TRAIL-induced caspase activation and apoptosis (Austin et al., 2006; Kohlhaas et al., 2007) . Importantly, Apo2L/TRAIL stimulation leads to a rapid, caspase-mediated cleavage of key clathrin-pathway components (AP2a, AP1/2b and the clathrin heavy chain), thereby disrupting clathrin-mediated endocytosis (Austin et al., 2006) . Notably, in HNU499 and Huh-7 hepatocarcinoma cell lines and HuCCT-1 and Mz-ChA-1 cholangiocarcinoma cells, stable expression of a dominant-negative dynamin mutant decreased Apo2L/ TRAIL-mediated apoptosis (Akazawa et al., 2009) . However, the latter results are difficult to assess, given that dynamin-dependent endocytosis has many cellular roles and its permanent disruption (rather than brief interruption through a temperature-sensitive dynamin mutant) may have unintended consequences. The caveolin pathway also has been proposed to modulate Apo2L/TRAIL signaling (Zhao et al., 2009) ; however, the contribution of this pathway to internalization of DR4 and/or DR5 requires further verification. Hence, although it seems clear that DR4 and DR5 undergo endocytosis on ligation, the biological significance of this event for apoptosis signaling by Apo2L/TRAIL remains unresolved (Figure 2 ).
New insights into the mechanism of caspase-8 activation Although the activation of caspase-8 through the extrinsic pathway has been extensively studied for over a decade, the events that mediate full activation of this enzyme are not completely understood.
Apoptosis signaling by Apo2L/TRAIL F Gonzalvez and A Ashkenazi Polyubiquitylation of caspase-8 drives aggregation and full activation. Recently, ubiquitylation has emerged as a crucial mechanism that controls full activation of caspase-8 . Jin et al. observed that caspase-8 is polyubiquitylated at the DISC in response to Apo2L/TRAIL. Ubiquitylation relies on the coordinated activities of E1 ubiquitin-activating, E2 ubiquitinconjugating and E3 ubiquitin-ligating enzymes and is counterbalanced by deubiquitinase (DUB) enzymes. Ubiquitin polypeptides are attached to protein substrates as monoubiquitin, or as polyubiquitin chains linked through internal lysines. Polyubiquitin chains linked at K48 often target proteins for proteasomemediated degradation, whereas chains linked through K63 frequently modulate trafficking and function of proteins (Pickart, 2004) . Immunoprecipitation of the Apo2L/TRAIL DISC, followed by mass spectrometry, revealed the association of the E3 ligase subunit Cullin 3 (CUL3) and the DUB A20 with the complex. Gain-and loss-of-function experiments indicated that a CUL3/ RbxI-based E3 ligase promotes caspase-8 ubiquitylation and activation on Apo2L/TRAIL ligation, whereas A20 reverses CUL3-mediated caspase-8 ubiquitylation and inhibits activation. Further results showed that the ubiquitin-binding protein p62/sequestosome-1 is also recruited to the DISC, but does not affect caspase-8 ubiquitylation. Rather, p62 associates with ubiquitylated caspase-8 and promotes its translocation from the receptor-based DISC to intracellular ubiquitin-rich protein aggregates or foci. This focal concentration of caspase-8 seems to facilitate its full activation, ultimately leading to effector-caspase engagement and apoptosis ( Figure 2 ). Biochemical analysis indicated that caspase-8 is polyubiquitylated on its C-terminal region (within the p10 subunit) and identified K461 as the likely principal conjugation site. Both K48-and K63-linked polyubiquitin chains were detected on caspase-8 after Apo2L/ TRAIL stimulation, and both linkages were required for caspase-8 activation on overexpression.
Remarkably, p62 and A20 have been implicated also in NF-kB signaling. p62 can promote the translocation of TRAF6 into ubiquitin-rich foci, promoting TRAF6-mediated activation of NF-kB (Moscat et al., 2007) . A20, which inhibits caspase-8 activation, also negatively regulates NF-kB activation by deubiquitylating RIP1 (Wertz et al., 2004) . Therefore, p62 and A20 provide potential nodes for coordination between the apoptosis and NF-kB signaling pathways (Figure 2 ).
The mitochondrial membrane as a platform for caspase-8 activation. A recent study has suggested an unusual role of mitochondria, and the mitochondrial lipid cardiolipin (CL), in Fas-mediated apoptosis signaling (Gonzalvez et al., 2008; Scorrano, 2008) . Experimental manipulation of cellular CL levels indicated that CL is required for efficient Fas-induced apoptosis in type II cells. Further investigation revealed that in response to Fas activation, caspase-8 relocates and inserts in the mitochondrial outer membrane through specific interaction with CL. On accumulation in the mitochondria, caspase-8 underwent oligomerization and full processing into its mature form; the latter events were required for mitochondrial cytochrome c release and subsequent apoptosis. These findings suggest that CL provides an activation platform for caspase-8 on the mitochondria and is important for efficient Fas signaling in type II cells. The signal that directs caspase-8 to the mitochondria has yet to be defined. It is possible that the localized activity of caspase-8 helps ensure that the cleavage of Bid is performed where it is functionally needed: on the surface of the mitochondria. Although Bid was first described as a cytosolic protein (Wang et al., 1996; Li et al., 1998; Luo et al., 1998) , several laboratories have reported its detection at the surface of mitochondria (Esposti et al., 2001; Grinberg et al., 2002; Tafani et al., 2002) . Moreover, CL promotes tBid binding to the mitochondrial outer membrane (Lutter et al., 2000; Gonzalvez et al., 2005a, b) . Further research is required to determine whether caspase-8 cleaves Bid directly at the mitochondrial surface. It will also be of interest to learn whether a mitochondrial platform contributes to caspase-8 activation in response to Apo2L/TRAIL.
Alternative signaling events regulated by Apo2L/TRAIL
Besides caspase activation, Apo2L/TRAIL can stimulate intracellular kinase signaling cascades, including the inhibitor of kB kinase (IKK), c-Jun N-terminal kinase (JNK) and p38 MAPK pathways. Overexpression experiments with DR4 and DR5 suggest that Apo2L/ TRAIL is much less potent than TNF-a at activating NF-kB (Chaudhary et al., 1997; Sheridan et al., 1997; Schneider et al., 1997a) . Activation of the IKK complex, composed of IKK-a, IKK-b and NEMO/IKK-g, leads to phosphorylation and consequent degradation of the inhibitor of kB (I-kB). This permits translocation of NF-kB to the nucleus, where it stimulates the transcription of genes that regulate apoptosis, inflammation and immunity (Lin et al., 2000) . Although Apo2L/TRAIL does not depend on RIP1 to signal apoptosis, it requires RIP1 for IKK activation (Lin et al., 2000) . Indeed, Apo2L/TRAIL activates NF-kB by promoting the recruitment of RIP1, TRAF2 and NEMO to an intracellular complex (called complex II), nucleated downstream of the DISC (Varfolomeev et al., 2005) (Figure 2 ). Complex II association requires FADD and caspase-8 but is physically separate from the ligandreceptor complex (Varfolomeev et al., 2005) . Moreover, complex II contains TRADD and caspase-10 (Jin and El-Deiry, 2006) . The biological significance of NF-kB activation by Apo2L/TRAIL is not fully understood. As NF-kB can induce the transcription of antiapoptotic genes such as c-FLIP, cIAP1, cIAP2, XIAP and Bcl-X L , its activity may serve to curtail Apo2L/TRAIL-induced apoptosis. Consistent with this notion, inactivation of NF-kB augmented Apo2L/TRAIL-mediated apoptosis during inflammation-induced growth of lung tumor metastases (Luo et al., 2004) . In addition, mice with a conditional knockout of NEMO in hepatocytes were Apoptosis signaling by Apo2L/TRAIL F Gonzalvez and A Ashkenazi more susceptible to apoptosis activation in liver cells by Flag-epitope-tagged, crosslinked Apo2L/TRAIL (Beraza et al., 2009) . Furthermore, mouse embryo fibroblasts deficient in TAK1, which transmits NF-kB stimulation signals emanating from RIP1, displayed elevated sensitivity to apoptosis induction by Apo2L/ TRAIL in connection with diminished expression of c-FLIP L (Lluis et al., 2010) . Although NF-kB activity may serve to set an a priori threshold for sensitivity to apoptosis induction by Apo2L/TRAIL, given that caspase activation by this ligand occurs rather rapidly, it is unlikely that induction of prosurvival genes downstream of DR ligation would be swift enough to provide significant protection except in cells that do not develop sufficient caspase activity in the first place. Alternatively, NF-kB activation by Apo2L/TRAIL may serve to recruit phagocytic cells through local induction of chemokines, such as IL-8 and MCP-1, to help remove apoptotic cells from tissues (Varfolomeev et al., 2005) . There is also evidence for a proapoptotic role of the NFkB pathway in Apo2L/TRAIL signaling. The overexpression of an NF-kB super-repressor in pancreatic carcinoma cells, or deletion of the c-Rel subunit of NFkB in mouse embryo fibroblasts rendered those cells resistant to Apo2L/TRAIL-induced apoptosis Ou et al., 2005) . It has been reported that Apo2L/TRAIL-induced NF-kB activation can promote survival, proliferation and invasiveness of certain cancer cell lines resistant to Apo2L/TRAIL-induced apoptosis (Ehrhardt et al., 2003; Ishimura et al., 2006) . However, the observed effects were modest; moreover, given that differences in biological activity may exist between recombinant soluble versions of Apo2L/TRAIL , the practical implications of these studies are difficult to assess, because biochemical characterization of the ligand variant used was not provided. Importantly, studies with mDR5-knockout mice suggest that this receptor is involved in suppressing innate immunity to pathogens by inhibiting, rather than stimulating, the NF-kB pathway (Diehl et al., 2004) . In agreement with these latter findings, lung tumors induced experimentally in mDR5-null mice display elevated levels of NFkB (Finnberg et al., 2008) . Although the molecular mechanism underlying DR5-mediated inhibition of NFkB remains unclear, these observations raise questions about the biological significance of NF-kB activation by Apo2L/TRAIL. Indeed, the physiological relevance of the observation that Apo2L/TRAIL can stimulate other intracellular kinase cascades such as the JNK, MAPK and PKB/Akt pathways has yet to be established as well (Lin et al., 2000; Secchiero et al., 2003; Zhang et al., 2003; Varfolomeev et al., 2005) (Figure 2 ).
Conclusions
The discovery of Apo2L/TRAIL in the mid 1990s and the identification of its two cognate DRs, DR4 and DR5, provided a unique new model system for interrogating the cell-extrinsic apoptosis pathway. Biochemical and genetic studies of this system have suggested that apoptosis signaling by DR4 and DR5 more closely resembles that of Fas, as compared with TNFR1 or DR3, involving the direct recruitment of FADD and caspase-8 into a DISC. Recent work has further elucidated key molecular determinants and events that have critical roles in DR-dependent apoptosis initiation. These advances include the following: (1) the demonstration that post-translational modification of DR4 and DR5 by O-glycosylation and palmitoylation is critical for ligand-induced receptor activation; (2) the detection of novel DISC-interacting proteins, including the ubiquitin E3 ligase subunit CUL3, the deubiquitinase A20 and the ubiquitinbinding protein p62; (3) the discovery that polyubiquitylation of caspase-8 by a CUL3/Rbx1-based E3 ligase, followed by binding to p62, drives caspase-8 into ubiquitin-rich intracellular foci, thus mediating its full activation downstream of the receptor-associated DISC. These advances provide basic mechanistic insights into apoptosis signaling; moreover, they present new translational opportunities for identifying susceptible tumors or sensitizing resistant ones to apoptosis-based cancer therapy.
